{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:01:20Z","timestamp":1777892480828,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Royal College of Physicians of Edinburgh"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:p>Imatinib, a tyrosine kinase inhibitor, is the mainstay of treatment for resected high-risk (adjuvant and metastatic) gastrointestinal stromal tumour (GIST) - a rare form of sarcoma. There has been recent research into the neuroprotective role and modulation of dopaminergic neurones by imatinib through the abl pathway in Parkinson's disease (PD). We describe two patients from a single cancer centre with concurrent diagnoses of PD and metastatic GIST receiving imatinib and standard PD management. The cases highlight a potential reduction in PD progression using Unified Parkinson's Disease Rating Scale. Further research into repurposing of imatinib for PD may provide additional management options for this neurodegenerative illness.<\/jats:p>","DOI":"10.4997\/jrcpe.2018.309","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T10:14:50Z","timestamp":1536228890000},"page":"242-245","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Possible Modulation of Concurrent Parkinson'S Disease in the Management of Metastatic Gist: A Review of Two Cases"],"prefix":"10.1177","volume":"48","author":[{"given":"T","family":"Watson-Fargie","sequence":"first","affiliation":[{"name":"Foundation Year 2 Doctor, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DG","family":"Grosset","sequence":"additional","affiliation":[{"name":"Consultant Neurologist, Department of Neurology, Institute of Neurosciences, Queen Elizabeth University Hospital, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"White","sequence":"additional","affiliation":[{"name":"Consultant Oncologist, Beatson West of Scotland Cancer Centre, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Cowie","sequence":"additional","affiliation":[{"name":"Consultant Oncologist, Beatson West of Scotland Cancer Centre, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,9,1]]},"reference":[{"key":"bibr1-jrcpe.2018.309","first-page":"81","volume":"1","author":"Maki RG","year":"2007","journal-title":"Gastrointest Cancer Res"},{"key":"bibr2-jrcpe.2018.309","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2015.10.031"},{"key":"bibr3-jrcpe.2018.309","author":"Sacha T","year":"2014","journal-title":"Mediterr J Haematol Infect Dis"},{"key":"bibr4-jrcpe.2018.309","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2007.131045"},{"key":"bibr5-jrcpe.2018.309","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25945"},{"key":"bibr6-jrcpe.2018.309","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22340"},{"key":"bibr7-jrcpe.2018.309","first-page":"153","volume-title":"Recent Developments in Parkinson's Disease Volume II","author":"Fahn S","year":"1987"},{"key":"bibr8-jrcpe.2018.309","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23429"},{"key":"bibr9-jrcpe.2018.309","doi-asserted-by":"publisher","DOI":"10.1097\/NRL.0b013e318251e6f2"},{"key":"bibr10-jrcpe.2018.309","doi-asserted-by":"publisher","DOI":"10.1172\/JCI29178"},{"key":"bibr11-jrcpe.2018.309","doi-asserted-by":"publisher","DOI":"10.1017\/S1462399409001148"},{"key":"bibr12-jrcpe.2018.309","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22798"},{"key":"bibr13-jrcpe.2018.309","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1006083107"},{"key":"bibr14-jrcpe.2018.309","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2012.05.007"},{"key":"bibr15-jrcpe.2018.309","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-006-0018-5"},{"key":"bibr16-jrcpe.2018.309","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.S22.004"},{"key":"bibr17-jrcpe.2018.309","unstructured":"National Institutes of Health. Nilotinib in Parkinson's disease (NILO-PD). 2017. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03205488?cond=nilotinib+AND+%22Parkinson+Disease%22 (accessed 21\/05\/18)."}],"container-title":["Journal of the Royal College of Physicians of Edinburgh"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.4997\/jrcpe.2018.309","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.4997\/jrcpe.2018.309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:30:27Z","timestamp":1777617027000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.4997\/jrcpe.2018.309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.4997\/jrcpe.2018.309"],"URL":"https:\/\/doi.org\/10.4997\/jrcpe.2018.309","relation":{},"ISSN":["1478-2715","2042-8189"],"issn-type":[{"value":"1478-2715","type":"print"},{"value":"2042-8189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}